Yahoo · Aug 28, 2026
CVRx Secures Devoted Health Coverage for Barostim Therapy
CVRX secures Devoted Health Medicare Advantage coverage for Barostim, expanding reimbursement access to about 466,000 members across 29 states.
CV
NASDAQ · CVRX
CVRx, Inc.
Healthcare · Medical - Devices
$3.02
Down-$0.02 (-0.66%)
Updated Sep 17, 2026, 2:17 PM
SID Score
3.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 220.41M
- P/E ratio
- -4.2
- Dividend yield
- 0.00%
- 52-week range
- $2.20 – $11.30
- Volume
- 415.89K
- Avg. volume
- 216.61K
Price performance
CVRX price history
1M range · 20 trading sessions · Daily adjusted prices
CVRX closed at $3.02 after 20 trading sessions, up 7.09% for the selected period.
- Last close
- $3.02
- Period change
- +7.09%
- Period low
- $2.82
- Period high
- $3.37
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $2.99 | $3.13 | $2.92 | $3.02 | 415.89K |
| Sep 15, 2026 | $2.99 | $3.08 | $2.85 | $3.00 | 494.94K |
| Sep 14, 2026 | $2.86 | $3.00 | $2.79 | $3.00 | 548.39K |
| Sep 11, 2026 | $2.86 | $2.901 | $2.75 | $2.88 | 1M |
| Sep 10, 2026 | $2.83 | $2.86 | $2.70 | $2.86 | 373.41K |
| Sep 9, 2026 | $2.90 | $2.95 | $2.76 | $2.83 | 555.24K |
| Sep 8, 2026 | $3.03 | $3.05 | $2.81 | $2.93 | 619.56K |
| Sep 4, 2026 | $2.99 | $3.11 | $2.96 | $3.05 | 856.03K |
| Sep 3, 2026 | $3.11 | $3.175 | $2.98 | $3.01 | 614.54K |
| Sep 2, 2026 | $3.06 | $3.16 | $2.962 | $3.07 | 530.03K |
| Sep 1, 2026 | $2.93 | $3.06 | $2.895 | $3.04 | 780.72K |
| Aug 31, 2026 | $2.97 | $2.99 | $2.81 | $2.96 | 737.78K |
| Aug 28, 2026 | $3.03 | $3.15 | $2.94 | $2.95 | 497.12K |
| Aug 27, 2026 | $3.25 | $3.29 | $3.02 | $3.04 | 449.03K |
| Aug 26, 2026 | $3.31 | $3.40 | $3.15 | $3.27 | 884.49K |
| Aug 25, 2026 | $3.17 | $3.42 | $3.1303 | $3.37 | 1.12M |
| Aug 24, 2026 | $2.99 | $3.29 | $2.86 | $3.15 | 1.62M |
| Aug 21, 2026 | $2.86 | $2.96 | $2.82 | $2.84 | 742.07K |
| Aug 20, 2026 | $2.81 | $2.9507 | $2.77 | $2.84 | 746.5K |
| Aug 19, 2026 | $2.75 | $2.85 | $2.73 | $2.82 | 586.68K |
Latest CVRX news
The latest Smart Investors Daily articles mentioning CVRX.
Stock researchCompany · Overview
CVRX research
Overview
Company profile and research snapshot.
Company profile
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $13.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 17, 2026 | Cantor Fitzgerald | Overweight | — |
| Aug 7, 2026 | Lake Street | Hold | — |
| Apr 14, 2026 | Canaccord Genuity | Buy | — |
| Feb 13, 2026 | Canaccord Genuity | Buy | — |
| Nov 6, 2025 | Canaccord Genuity | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 24, 2026
CVRx Shareholder Urges Board To Launch Sale Process To Unlock Barostim’s Strategic Value
Delivers Letter to the CVRx Board Highlighting Significant Value Proposition of Barostim to a Large Medical Device Company with Established Infrastructure to Capitalize on the Product's Market PositionBLOOMFIELD
Benzinga · Aug 17, 2026
Cantor Fitzgerald Maintains Overweight on CVRx, Lowers Price Target to $5
Cantor Fitzgerald analyst Sarah James maintains CVRx (NASDAQ:CVRX) with a Overweight and lowers the price target from $13 to $5.
Yahoo · Aug 13, 2026
CVRx (CVRX) Q2 2026 Earnings Call Transcript
U.S. heart failure revenue surged 21% amid reimbursement gains and sales expansion challenges.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
